摘要
目的 观察经皮椎体成形术（PVP）联合唑来膦酸治疗脊柱转移癌的疗效.方法 将50例脊柱转移癌患者按随机数字表法分为对照组和治疗组,每组25例.对照组采用唑来膦酸4 mg,每间隔28 d静脉滴注1次;治疗组在对照组基础上联合PVP.观察并比较两组术后3个月视觉模拟量表评分、活动能力评分及止痛药使用评分,并记录患者术后再发骨折等情况.结果 治疗后3个月,治疗组视觉模拟量表评分、活动能力评分及止痛药使用评分较对照组均明显降低[（2.00±0.17）分比（7.84±0.18）分、（2.12±1.38）分比（3.21±0.13）分、（1.47±0.10）分比（3.30±0.09）分],差异有统计学意义（P＜0.01或＜0.05）;治疗组再发骨折2例（8％,2/25）,对照组9例（36％,9/25）,两组再发骨折率比较差异有统计学意义（P＜0.05）.结论 PVP联合唑来膦酸治疗脊柱转移癌具有创伤小、手术时间短、快速缓解患者疼痛症状的特点,可以明显提高患者生存质量,值得临床推广应用.
Objective To observe the efficacy of percutaneous vertebroplasty （PVP） combined with zoledronic acid in treatment of spinal metastatic carcinoma.Methods Fifty cases of spinal metastatic carcinoma were divided into control group and treatment group by random digits table method with 25 cases each.The control group was given zoledronic acid 4 mg,intervals of 28 d intravenous drip 1 time.The treatment group was given PVP besides zoledronic acid.The visual analog scale score,activity ability score and analgesic usage score after treatment for 3 months were observed and compared.The quality of life was evaluated and the occurrence of relapse of fracture was also recorded.Results After treatment for 3 months,the visual analog scale score,activity ability score and analgesic usage score were （2.00 ± 0.17）,（2.12 ± 1.38）,（1.47 ± 0.10） scores in treatment group,and （7.84 ± 0.18）,（3.21 ± 0.13）,（3.30 ± 0.09） scores in control group,and there were significant differences between two groups （P 〈 0.01 or 〈 0.05）.The occurrence of relapse of fracture was 2 cases （8%,2/25） in treatment group and 9 cases （36%,9/25） in control group,and there was significant difference between two groups （P 〈 0.05）.Conclusions PVP combined with zoledronic acid in treatment of spinal metastatic carcinoma has many advantages such as small incision,short surgery time and rapid relief from pain.It can obviously improve the quality of life,and it is worthy of spreading in the clinic.
出处
《中国医师进修杂志》
2015年第2期102-104,共3页
Chinese Journal of Postgraduates of Medicine
关键词
椎体成形术
脊柱疾病
肿瘤转移
唑来膦酸
Vertebroplasty
Spinal diseases
Neoplasm metastasis
Zoledronic acid
